1. Introduction {#sec0005}
===============

In the final days of 2019, a pneumonia of unknown etiology with fever, breathing difficulties, and invasive lung lesions was reported in Wuhan China by the WHO. On January 7, 2020, Chinese scientists identified the etiologic agent as a new type of coronavirus, with the genome sequence available five days later \[[@bib0005]\]. WHO changed the status of the disease to a pandemic on March 11, 2020, because of the rapid increase in cases and worldwide spread \[[@bib0005]\]. As of June 17, 2020, the total number of Coronavirus disease 19 (COVID-19) cases worldwide was approximately 8 million and the total number of deaths was approximately 450,000, a death total ratio of 5.48 percent \[[@bib0010]\]. At present, there is no protective vaccine or approved treatments available.

2. Overview of the SARS-CoV-2 {#sec0010}
=============================

The virus, which is the cause of the COVID-19 was named as *Severe Acute Respiratory Syndrome-related Coronavirus* (SARS-CoV-2) by *Coronaviridae* Study Group of the International Committee on Taxonomy of Viruses ([Fig. 1](#fig0005){ref-type="fig"} a). SARS-CoV-2 is a betacoronavirus, in the Coronaviridae family along with two other species that infect humans, SARS-CoV, and MERS-CoV \[[@bib0015]\].Fig. 1Overview of the SARS-CoV-2 a. Taxonomy of the virus; b. Viral transcriptome; c. Pathophysiology.Fig. 1

The genomic structure of the virus is a positive-sense, single-stranded RNA which is approximately 30 kb (29,903 nucleotides). The viral RNA is packaged by nucleocapsid proteins and this structure is surrounded by a bilayer lipid corona structure which includes membrane, envelope, and spike proteins ([Fig. 1](#fig0005){ref-type="fig"}b). The transcriptome contains the *open reading frame (ORF) 1ab, S, ORF3a, E, M, ORF6, ORF7a, ORF7b, ORF8, N,* and *ORF10* genes, respectively. *ORF1ab* is cleavaged to nonstructural proteins (nsp). Among them, nsp12 has RNA-dependent RNA polymerase activity which performs replication and transcription of the viral genome using it as a template. The functions of other *ORF*s, which encode accessory proteins, are not yet clearly described \[[@bib0020]\]. The *S* gene encodes the *Spike* glycoprotein that binds to the human angiotensin-converting enzyme 2 (*ACE2*) receptor to infect the host cells \[[@bib0025]\]. While *Envelope* and *Membrane* proteins encoded by *E* and *M* genes, associate with the bilayer lipid envelope structure on the outer surface of the virus, *N* codes the *Nucleocapsid* protein that directly interacts with the viral genome \[[@bib0030]\].

The *S* protein of virion binds to the *ACE2* receptor of the cell that will be infected by the virus ([Fig. 1](#fig0005){ref-type="fig"}c). In the process following the binding, it is suggested that proteases especially *TMPRSS2*, on the surface of the host cell can strengthen binding and trigger receptor-mediated endocytosis by causing conformational changes in the *S* glycoprotein \[[@bib0025]\]. The early endosome carrying the virion matures towards the late endosome during vesicular traffic process and the gradual increase in the endosomal lumen acidity causes the release of the viral genome to the cytoplasm \[[@bib0035]\]. Firstly, *ORF1ab* is translated using the viral RNA, and its cleavage forms the RNA-dependent RNA polymerase which is involved in both replication and transcription of structural proteins. Using these transcripts, cytoplasmic ribosomes translate the nucleocapsid protein, and ER-bound ribosomes translate the spike, envelope, and membrane proteins into the ER lumen. Nucleocapsid packed viral RNA is encapsulated within the vesicle which carries spike, envelope, and membrane proteins on its membrane in the Endoplasmic Reticulum Golgi Intermediate Compartment (ERGIC). Finally, a complete virion is released to the extracellular region by exocytosis \[[@bib0040]\].

3. Overview of the COVID-19 {#sec0015}
===========================

3.1. Symptoms {#sec0020}
-------------

SARS-CoV-2 is transmitted from human to human with droplets and from the mucosal surfaces of the nose, mouth, and eyes \[[@bib0045]\]. It is thought that the majority of the SARS-CoV-2 infected individuals are asymptomatic depending on their general health conditions and age. Fever, dry cough, fatigue or weakness, and dyspnea are the most common (\>50%); myalgia, chest oppression or pain, diarrhea, loss of or poor appetite, shortness of breath, expectoration, anorexia are common (\<50% and \>10%); headache, chest pain, sore throat, vomiting, loss of smell and taste are the less common (\<10%) symptoms of the diagnosed cases \[[@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095], [@bib0100]\].

3.2. Diagnosis {#sec0025}
--------------

In addition to general symptoms and laboratory findings, chest computed tomography (CT), rapid antibody-based methods, and molecular tests including Real-Time Reverse Transcriptase--PCR are utilized for diagnosis of COVID-19 \[[@bib0050]\]. SARS-CoV-2 was isolated from different clinical samples including upper and lower respiratory tract passages, blood, and stool. However the infectious nature of the live virus is not exactly defined, with the exception of the respiratory tract samples \[[@bib0105]\]. Based on Real-Time Reverse Transcriptase--PCR test results, the infectivity rate decreases in virus from bronchoalveolar lavage, sputum, throat, nasal and pharyngeal swabs, respectively \[[@bib0110]\]. Similarly, the infectivity rate appears to be higher in the early and progressive stages of the disease, compared to the recovery stage. The high viral load and infectious properties of the respiratory samples are thus suggestive evidence of respiratory transmission \[[@bib0115]\].

3.3. Risk factors {#sec0030}
-----------------

Advanced age (≥ 65 years) is defined as the most common risk factor. Comorbidities - hypertension, cardiovascular diseases, diabetes, chronic obstructive pulmonary diseases, malignancies, chronic kidney or hepatic diseases, asthma, or infectious diseases such as tuberculosis, and hepatitis - have been identified as other risk groups \[[@bib0050],[@bib0055],[@bib0065],[@bib0085],[@bib0095],[@bib0120]\]. Although smoking is the main risk factor for various diseases especially lung cancer, it is not classified as a risk factor of COVID-19 as yet \[[@bib0125]\]. Various genetic factors may also affect the prognosis of COVID-19; for example, the phenotypes of HLA-B \*46:01 and HLA-B\*15:03 affect the severity of infection by causing low and high binding affinity of SARS-CoV-2 to cells, respectively \[[@bib0130]\].

3.4. Complications {#sec0035}
------------------

Complications triggered by COVID-19 are the main factors affecting disease severity and death. The most common complication of the COVID-19 is acute respiratory distress syndrome (ARDS). It is characterized by the appearance of ground-glass opacities in the lungs and results in serious respiratory failure and secondary complications, including multiple organ failure related to insufficient oxygenation levels \[[@bib0100],[@bib0120],[@bib0135]\]. Cytokine release syndrome or cytokine storm (***See "4- Cytokine storm and COVID-***19″ ***section***), hemophagocytic lymphohistiocytosis, and septic shock are frequently seen as complications from hyperactivation of the immune system \[[@bib0140], [@bib0145], [@bib0150], [@bib0155], [@bib0160]\]. Development of the autoimmune diseases including neurodegenerative disorders like Guillain Barre Syndrome, hematologic disorders like autoimmune hemolytic anemia is reported during COVID-19 treatment \[[@bib0165],[@bib0170]\]. Acute cardiac, kidney, and liver injury are reported as common complications \[[@bib0100],[@bib0120],[@bib0135]\]. Although meningitis and encephalitis are also reported as less common complications of COVID-19, other bacterial or viral co-infections are quite frequent and they may result in deaths \[[@bib0090],[@bib0175]\].

3.5. Current therapies {#sec0040}
----------------------

No treatment or drug has yet been approved, although different therapeutic approaches are currently being tested against the symptoms of COVID-19. Current treatment applications are separated into two subgroups: the first group of the treatment strategies includes antiviral drugs and immune-based therapies to overcome viral infection; the second group comprises antithrombotics, ventilation or oxygen therapies, used for secondary complications.

Remdesivir (GS-5734, Gilead Sciences) is an RNA-dependent RNA polymerase inhibitor, used against RNA viruses such as *Ebolaviruses,* although it has not yet been approved for any indication \[[@bib0180],[@bib0185]\]. Chloroquine (or hydroxychloroquine) is an approved antimalarial drug that increases the pH of lysosomes and inhibits autophagy by suppressing lysosome-autophagosome fusion \[[@bib0190]\]. This autophagy inhibitor is a part of the current COVID-19 treatment protocol because it inhibits the endocytic pathway which allows virus entry into the cell and activation after binding to the *ACE2* receptor \[[@bib0195]\]. Nevertheless, current indicated that chloroquine has no beneficial value in seriously ill patinets. HIV protease inhibitors have been approved for use in treatment of HIV that function to inhibit proteolysis of viral proteins necessary to complete the HIV life cycle \[[@bib0200]\]. It is predicted that protease inhibition performed with agents such as Lopinavir/Ritonavir (Kaletra, Abbott Laboratories) may also be effective against SARS-CoV-2 \[[@bib0205]\].

The use of plasma (known as convalescent plasma therapy) or immune globulins from recovered individuals is being tested in clinical trials to help activate the immune system against SARS-CoV-2 in patients. Also, interferons (interferon alfa and interferon beta) are being tested for the same purpose \[[@bib0210]\]. Numerous clinical studies aimed to induce adaptive immunity are currently underway by different research teams \[[@bib0215],[@bib0220]\].

It has been reported that the infection-related increase of coagulation parameters especially the D-dimer (normal range \<0.5 μg/ml) is directly proportional to the severity of the disease. Coagulation abnormalities cause disseminated intravascular coagulation and triggers venous thromboembolism and pulmonary embolism which are among the main causes of COVID-19 related death. Antithrombotic and anticoagulant drugs including heparin, warfarin, direct-acting oral anticoagulants are used to protect against the development of coagulation and thromboembolism complications during the treatment process \[[@bib0225]\].

3.6. Genetic alterations in COVID-19 {#sec0045}
------------------------------------

Various genetic alterations have been reported that could potentially be used as therapeutic targets during COVID-19 infection ([Fig. 2](#fig0010){ref-type="fig"} ). These variations especially include inflammation and immune response regulation \[[@bib0050],[@bib0055],[@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085],[@bib0095],[@bib0120],[@bib0135],[@bib0145],[@bib0155],[@bib0160],[@bib0230], [@bib0235], [@bib0240], [@bib0245], [@bib0250], [@bib0255], [@bib0260], [@bib0265]\]. Furthermore, increased expression of *ACE2* and *TMPRSS2* may contribute to complications in the heart, lungs, and different organs of the nervous system \[[@bib0235],[@bib0270]\].Fig. 2Genetic alterations in different tissues and blood of COVID-19 patients compared to control cells.Fig. 2

4. Cytokine storm and COVID-19 {#sec0050}
==============================

As a consequence of SARS-CoV-2 infection, a cytokine storm syndrome is triggered by dysregulated immune responses; the cytokine storm is characterized by a high inflammatory response, including elevated levels of cytokines and immune cells that infiltrate and destroy organs and cause lung lesions, respiratory dysfunction, multiple organ damage, and death \[[@bib0140]\]. Cytokines are a group of immunoregulatory cell-cell communication molecules including different subtypes named chemokine (chemotaxis cytokine), interleukin (leukocyte related cytokine), lymphokine (lymphocytes-related cytokine), monokine (monocytes-related cytokine) and interferons. Although originally thought to be secreted by specific immune cells, it is now recognized that nonimmune cells, fibroblasts or endothelial cellsrespond to inflammation or injury, as well as monocytes, macrophages, B- and T-lymphocytes. These cytokines are both cause and effect of the immune response and include both pro- and anti-inflammatory molecules \[[@bib0275]\].

4.1. The JAK/ STAT pathway {#sec0055}
--------------------------

Cytokines regulate different cellular and immune processes and their activation is controlled by the JAK/STAT signalling pathway \[[@bib0280]\]. The Janus kinases (JAKs) and the signal transducers and activators of transcriptions (STATs) form one of the main regulatory cell signaling pathways ([Fig. 3](#fig0015){ref-type="fig"} ). The JAK non-receptor tyrosine kinase family includes Jak1, Jak2, Jak3, and Tyrosine kinase 2 (Tyk2) proteins. Their unique structure consists of seven JAK homology domains (JH1-7); at the carboxy-terminal, are two kinase domains (JH1 and JH2). This family is named for the mythological *Janus* god because of the two headed tandem kinase domains. The JH1 domain is a catalytic component and a second kinase domain is a pseudo-kinase JH2 that has an autoregulatory suppressor function. JH3 is a Src homology (SH2) domain and the activated SH2 generates a binding site for STAT transcription factors. At the amino terminal end is a receptor-interacting FERM domain comprising JH4-7 (Band 4.1, ezrin, radixin, moesin) \[[@bib0285]\]. The JAK non-receptor tyrosine kinases receive numerous different extracellular signals (growth factor, cytokine, and hormone) from host receptors and transfer these responses to the nucleus via the intracellular STATs. When extracellular signals are received by the specific JAK-associated receptor, a conformational change occurs that causes autophosphorylation on the tyrosines of the JAKs, and subsequent dimerization of the STATs. Dimerized STATs are directed into the nucleus and trigger transcription of the immune regulatory, apoptotic, cell cycle, and differentiation related genes. The STAT protein family includes STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6, and all contain an N-terminal, coiled-coil domain involved in protein-protein interactions, DNA-binding domain for sequence-specific DNA binding andnuclear localization, a linker region, an SH2 domain involved in dimerization and protein association, and a transactivation domain (TAD) that carries conserved tyrosine residues that are phosphorylation sites for host kinases \[[@bib0290]\]. Depending on the physiological signal, the JAK/STAT pathway regulates critical cellular homeostasis processes including immune response, proliferation, differentiation, migration, and apoptosis\[[@bib0295]\].Fig. 3The schematic structures of the JAK and STAT proteins and overview of the JAK/STAT pathway.Fig. 3

The IL6/JAK/STAT3 signaling pathway represents a specific branch of the JAK/STAT pathway that includes IL6, an essential pleiotropic cytokine produced by B cells T cells, dendritic cells, and macrophages to generate an immune response or inflammation. Binding of IL6 to its specific receptor (IL6 receptor-subunit alpha IL6R) triggers a heterohexameric complex with IL6 receptor subunit-β (gp130, IL6ST) and activates the IL6/JAK/STAT3 pathway, that includes activation of inflammation-related downstream targets \[[@bib0290]\].

IL6 is is one of the pivotal inflammatory cytokines upregulated in influenza, vaccinia, hepatitis B and C, Crimean-Congo hemorrhagic fever, and human immunodeficiency virus infections in humans \[[@bib0300]\]. In the context of COVID-19 cytokine storm, IL6 is likewise one of the most highly expressed cytokines; elevated serum levels of IL6 are considered one of the main indicators of poor prognosis in SARS-CoV-2 infection. The local inflammatory response, generated in part through IL6, also spreads throughout the body and contributes to cytokine release and acute respiratory distress syndromes, as well as organ damage. Different therapeutic strategies to overcome hyper-inflammation include the use of JAK/STAT pathway inhibitors and particularly anti-IL6 inhibitors \[[@bib0140]\].

5. Overview of the ruxolitinib and effect mechanisms {#sec0060}
====================================================

The first approved JAK inhibitor was ruxolitinib, followed by other JAK inhibitors including baricitinib, upadacitinib, tofacitinib, peficitinib, and fedratinib \[[@bib0305], [@bib0310], [@bib0315]\] that are under clinical investigation for the treatment of the cytokine storm. Among these, baricitinib (LY3009104, INCB028050, Olumiant, Eli Lilly) was the second JAK1 and JAK2 inhibitor, approved in 2018 for treatment of rheumatoid arthritis. In addition to its anti-inflammatory effects, baricitinib also inhibits virus endocytosis, indicating a dual specificity inhibitor \[[@bib0320]\]. And although clinical studies are underway, there is a caveat - baricitinib may increase patient vulnerability to co-infection, virus reactivation, lymphocytopenia, and neutropenia, thus indicating that it may not be an ideal treatment option \[[@bib0325]\]. A similar situation is encountered with interleukin inhibitors. Tocilizumab, an approved IL6 receptor antagonist, has been shown to reduce cytokine release syndrome symptoms in severe patients COVID-19 \[[@bib0330]\], but may also contribute to an increased risk of death by increasing immunosuppression in severely ill patients \[[@bib0150]\].

5.1. Ruxolitinib {#sec0065}
----------------

Ruxolitinib (INCB018424; Jakavi; Incyte Corporation) is a potent JAK1 and JAK2 inhibitor that blocks JAK kinase activity and prevents STAT activation and nuclear translocation. Ruxolitinib was approved by the FDA in November 2011, December 2014, and May 2019 for the treatments of Myelofibrosis, Polycythemia Vera, and Acute Graft-Versus-Host Disease, respectively to reduce the high level of cytokine release associated with these disorders. Therefore, ruxolitinib has begun to take its placein the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and lupus erythematosus, as well as other allergic and inflammatory diseases \[[@bib0335]\]. Ruxolitinib also inhibits IL6/JAK/STAT3 pathway, thus reducing circulating IL6 levels \[[@bib0340],[@bib0345]\].

5.2. Ruxolitinib and viral infections {#sec0070}
-------------------------------------

The potential of ruxolitinib in the treatment of different inflammatory conditions is also being investigated.

### 5.2.1. Immunosuppression {#sec0075}

Ruxolitinib is used in both acute and chronic graft versus host disease from allogeneic hematopoietic stem cell transplantation. \[[@bib0350]\]. Hemophagocytic lymphohistiocytosis, a rare secondary disease triggered by viral infection or autoimmune disease, in which a hyper-activated immune response may causesevere complications; ruxolitinib has been shown to suppress cytokine levels and the JAK/STAT pathway in Epstein-Barr Virus (EBV)-associated hemophagocytic lymphohistiocytosis \[[@bib0355]\].

### 5.2.2. Antiviral efficacy {#sec0080}

The anti-viral properties of ruxolitinib may have activity against Human Immunodeficiency Virus (HIV) and EBV infections. Ruxolitinib has been shown to inhibit HIV-1 replication in lymphocytes and macrophages and to suppress HIV-1 reactivation \[[@bib0360], as well as to inhibit production of inflammatory cytokines such as IL1β, IL2, IL5, IL6, IL7, IL13, IL15, and IFNG \[[@bib0365], [@bib0370], [@bib0375]\]. Similarly, the anti-viral potential of ruxolitinib is also indicated in EBV infection where ruxolitinib inhibits EBV-infected PBMC proliferation and reduces elevated inflammatory cytokines by inhibition of STAT3 \[[@bib0380],[@bib0385]\].

### 5.2.3. Opportunistic infections {#sec0085}

Because the JAK/STAT pathway is a primary signal pathway, suppression of this pathway can also result in the emergence of opportunistic infections. The development of Polyomavirus (JC-Virus and BK-Virus) related fatal encephalopathy and meningitis has been reported during ruxolitinib treatment \[[@bib0390],[@bib0395]\]. Because the JAK/STAT pathway inhibits Zika Virus (ZIKV) and Hepatitis C Virus (HCV), members of the *Flaviviridae* family, it is suggested that ruxolitinib may actually increase viral replication \[[@bib0400],[@bib0405]\]. Hepatitis B Virus (HBV) reactivation has also been reported due to ruxolitinib treatment \[[@bib0410]\]. Infections of different *Herpesvirus* family members which include Varicella-Zoster Virus (VZV), EBV, and Cytomegalovirus (CMV), have also been reported. Development of gastric ulcer and meningoencephalitis due to EBV and VZV infections has been reported in patients with myelofibrosis and polycythemia vera treated with ruxolitinib, respectively \[[@bib0415],[@bib0420]\]. Ruxolitinib has also been associated with reactivation of CMV, VZV, and EBV during myelofibrosis, graft versus host disease, and myelodysplastic syndrome treatments \[[@bib0425], [@bib0430], [@bib0435], [@bib0440]\]. Reactivation causes secondary diseases that include lymphoproliferative disorders \[[@bib0445]\].

6. Potential interactions between ruxolitinib and COVID-19 {#sec0090}
==========================================================

Since ruxolitinib is well-toleratedand used in the elderly population at present, it is a powerful candidate to overcome the hyperimmune syndrome that arises in COVID-19 patients \[[@bib0340]\]. A number of clinical trials assessing the efficacy of ruxolitinib in COVID-19 related symptoms are ongoing ([Table 1](#tbl0005){ref-type="table"} ).Table 1Clinical trials including ruxolitinib.Table 1Trial IDNameSponsorDoseDesignPatients & Medical conditionTime frameStatusEUCTR2020-001662-11-DERUXCOVIDNovartis Pharma AGOnce daily 5 mg•Phase 3•Randomized•Double-blind•Placebo-controlled•64 patient•COVID-19 associated cytokine storm•29 days•MortalityREUCTR2020-001459-42-DKRuxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.Zealand University Hospital-DenmarkOnce daily 10 to 40 mg•Phase 2•Non-randomized•Open label•40 patients•COVID-19 Pneumonia•30 days•MortalityOChiCTR2000029580Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trialDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology- China•Randomized•Single-blind•35 patients•COVID-19 diagnosed•Positive serum antibodies (IgM or IgG)•7 daysR2020-001777-71Ruxolitinib therapy to avoid Ventilation and improve outcome for deteriorating COVID-19 patients -- RAVENGuy's and St Thomas\' NHS Foundation Trust- UK\
Novartis Pharmaceuticals UK Ltd- free of charge drug supply•Phase 4•Non-randomized•Open label•59 patients•Proven COVID-19•28 daysONCT04348071Safety and Efficacy of Ruxolitinib for COVID-19University of Colorado, Denver- USATwice daily 10 mg•Phase 2•Phase 3•Single arm•Open label•80 patients•29 days•MortalityNYRNCT04354714Ruxolitinib to Combat COVID-19Washington University School of Medicine- USA\
Collobrator Incyte CorporationTwice daily 5 mg and 10 mg•Phase 2•Open label•25 patients•Positive test for SARS-CoV-2 RNA•Immune-hyperactivation•29 days•MortalityWNCT04377620Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)Incyte CorporationTwice daily 5 mg and 15 mg•Phase 3•Randomized•Double-blind•Placebo-controlled•500 patients•SARS-CoV-2 infection confirmed•29 days•MortalityRNCT04366232Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer- FranceTwice daily 5 mg•Phase 2•Randomize•Controlled•50 patients•Confirmed SARS-CoV-2 infection by PCR•29 days•MortalityNYRNCT04338958Ruxolitinib in Covid-19 Patients With Defined HyperinFlammation (RuxCoFlam)University of Jena- GermanyTwice daily 10 mg or 20 mg•Phase 2•Single arm•Non-randomized•200 patients•COVID-19 stage II and stage III•Hyper-inflammation•7 daysRNCT04334044Treatment of SARS caused by COVID-19 with RuxolitinibGrupo Cooperativo de Hemopatías Malignas -MexicoTwice daily 5 mg•Phase 1•Phase 2•20 patients•Diagnosed COVID-19•7 daysRNCT04331665Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 PneumoniaUniversity Health Network, Toronto- USATwice daily 10 mg (for 14 days) 5 mg, (for 2 days) Once daily 5 mg (for 1 day)•Single arm•Open label•64 patients•COVID-19 infection diagnosed by nasopharyngeal sample•9 monthNYRNCT04374149Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSPrisma Health-UpstatePlasma excahange and Once daily 5 mg (for14 days)•Phase 2•Non-randomized•Open label•20 patients•Positive for COVID-19 by PCR•14 dayNYRNCT04359290Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil)Philipps University Marburg Medical Center- GermanyTwice daily 10 mg to 15 mg•Phase 2•Open label•15 patients•Laboratory-confirmed SARS-CoV-2 infection•Cytokine release syndrome (CRS)•Increased activation of the JAK/STAT pathway•28 daysNYRNCT04355793Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionIncyte CorporationTwice daily 5 mg starting dose•Open label•COVID-19 related cytokine stormANCT04361903COVID-19: Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE StudyAzienda USL Toscana Nord Ovest- ItalyTwice daily at least 20 mg (for the first 48 hours)•Observational•Retrospective•Monocentric•Non-profit•13 patients•COVID-19 diagnosed•15 daysNYRNCT04414098Ruxolitinib in the Treatment of Covid-19Marcelo Iastrebner- Argentina\
Collaborator: NovartisTwice daily 5 mg•Phase 2•Experimental•Open label•Prospective•100 patients•SARS-Cov2 infection confirmed by PCR test•14 daysNYRNCT04337359Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 IllnessNovartis PharmaceuticalsOnce daily 5 mgANCT04424056An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease (INFLAMMACOV)Assistance Publique Hopitaux De Marseille- FranceDifferent combinations with anakinra, tocilizumab•Phase 3•Randomized•Open label•216 patients•Proven COVID-19•28 daysNYRNCT04348695Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19. (Ruxo-Sim-20)Hospital Universitario Madrid Sanchinarro-Madrid- SpainTwice daily 5 mg (7 days) Twice daily 10 mg (following 7 days) combination with simvastatin•Phase 2•Randomized•Open label•94 patients•SARS-Cov2 infection confirmed by PCR test•14 daysR\*Collaborator: Apices Soluciones S.L.NCT04403243COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT)Lomonosov Moscow State University Medical Research and Educational Center- RussiaTwice daily 5 mg•Phase 2•Randomized•Open label•70 patients•45 daysR[^1]

To determine the potential molecular efficacy of ruxolitinibon genetic alterations,molecular pathways that include altered genes were determined by the KEGG Pathway Database and the STRING Database Version 11 ([Fig. 4](#fig0020){ref-type="fig"} ). Ruxolitinib reduced the expression of inflammatory biomarkers at both the gene and protein levels in different cells ([Table 2](#tbl0010){ref-type="table"} ).Fig. 4Potential interactions between ruxolitinib and COVID-19 related genetic alterations.Fig. 4Table 2Genetic alterations are directly targeted by ruxolitinib in COVID-19.Table 2GenesRegulation in COVID-19ReferenceEffects of ruxolitinibReference***CBL***Downregulated after treatment in severe cases (PBMC)\[[@bib0070]\]Inhibits CBL mutant Pluripotent Stem Cells\[[@bib0450]\]***CXCL10***Upregulated in COVID-19 patients PBMC (compared to normal PBMC) and elevated blood level in severe patients\[[@bib0160],[@bib0245],[@bib0260]\]Downregulates the expression level in macrophages\[[@bib0455]\]***IL10***Upregulated in COVID-19 patients PBMC (compared to normal PBMC)and elevated blood level in severe patients\[[@bib0050],[@bib0055],[@bib0245],[@bib0250],[@bib0265],[@bib0070],[@bib0075],[@bib0080],[@bib0090],[@bib0095],[@bib0120],[@bib0135],[@bib0155]\]Decreases secretion in macrophages\[[@bib0460]\]***IL18***Upregulated COVID-19 patients PBMC (compared to normal PBMC)\[[@bib0245]\]Downregulates IL18 expression levels in lymphoblasts\[[@bib0345]\]***IL2***Elevated blood level in severe patients\[[@bib0155]\]Reduces IL2 levels in T cells\[[@bib0365]\]***IL2RB***Downregulated after treatment in severe cases (PBMC)\[[@bib0070]\]Inhibits JAK/STAT pathway activating IL2RB mutant Ba/F3 cells\[[@bib0465]\]***MCL1***Downregulated after treatment in severe cases (PBMC)\[[@bib0070]\]Downregulates expression level in lymphoblasts\[[@bib0470]\]***PDCD1***Increased levels on T cells\[[@bib0250]\]Decreases PDCD1 levels in T cells\[[@bib0475]\]***CCL2***Upregulated COVID-19 patients BALF (compared to normal BALF) Elevated blood level in severe patients\[[@bib0160],[@bib0245]\]Reduces secreted protein levels in bone marrow mesenchymal stromal cells\[[@bib0480]\]***CRP***Elevated blood level in severe patients\[[@bib0050],[@bib0060],[@bib0065],[@bib0090],[@bib0145]\]Reduces CRP level\[[@bib0485]\]***IL1B***Elevated blood level in severe patients\[[@bib0055],[@bib0075],[@bib0135]\]Downregulates expression in T cells\[[@bib0490]\]***IL4***Elevated blood level in severe patients\[[@bib0135]\]Reduces IL4 levels in patients\[[@bib0495]\]***IL6***Elevated blood level in severe patients\[[@bib0050],[@bib0055],[@bib0145],[@bib0155],[@bib0160],[@bib0250],[@bib0265],[@bib0330],[@bib0500],[@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085],[@bib0095],[@bib0120],[@bib0135]\]Downregulates IL6 expression level in lymphoblast\[[@bib0345]\]***TNF***Elevated blood level in severe patients\[[@bib0055],[@bib0075],[@bib0160]\]Reduces the expression in mast cells\[[@bib0505]\][^2]

7. Conclusion {#sec0095}
=============

It is clear that ruxolitinib has an important potential in overcoming complications caused by immune hyperactivation related to the JAK/STAT signaling pathway. Since the JAK/STAT pathway is associated with the induction of multiple molecular immune pathways, inhibition of this pathway may result in the inhibition of several cellular responses Considered together, ruxolitinib has potential in the treatment of COVID-19 infection; however, adverse effects such as opportunistic infections as a result of immune suppression must also be considered.
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[^1]: *A available; NYR* not yet recruiting; *O* ongoing; *R* recruiting; *W* withdrawn.

[^2]: PBMC peripheral blood mononuclear cells; BALF bronchoalveolar lavage fluid cells.
